Gilboa Therapeutics
Gilboa Therapeutics43About
What does Gilboa Therapeutics do?
Gilboa Therapeutics is a preclinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. Their mission is to enable more patients to respond to therapies and improve outcomes by harnessing the power of the patient's immune system with their proprietary SolidT technology.
Where is Gilboa Therapeutics headquartered?
Gilboa Therapeutics is headquartered in Tel Aviv, Israel.
When was Gilboa Therapeutics founded?
Gilboa Therapeutics was founded in 2017.
What industry does Gilboa Therapeutics operate in?
Gilboa Therapeutics operates in Biopharmaceuticals, Immunotherapy, Cancer Treatment, Biotechnology, Biotech, Drug Discovery.
How many employees does Gilboa Therapeutics have?
Gilboa Therapeutics has approximately 2 people on record.
What is Gilboa Therapeutics's current status?
Gilboa Therapeutics's current operating status is: Inactive.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Strength of the site’s backlink profile, on the industry-standard 0-100 scale. Licensed third-party data, not our opinion.
Star ratings come from visitors, one per person per profile, and are shown exactly as given: we do not weight, curate or filter them. Reviews are published in full alongside the rating that accompanied them.
No comments yet. Be the first to share your take.